FDA/CDC

FDA approves immunotherapy combo for advanced RCC


 


The recommended schedule and dose is 3 mg/kg nivolumab, followed by 1 mg/kg ipilimumab, on the same day every 3 weeks for four doses, then 240 mg nivolumab every 2 weeks or 480 mg every 4 weeks, the FDA said.

Nivolumab is marketed as Opdivo and ipilimumab as Yervoy by Bristol-Myers Squibb.

Next Article:

Do industry payments increase prescribing for some targeted therapies?

Related Articles